<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887770</url>
  </required_header>
  <id_info>
    <org_study_id>D1710C00006</org_study_id>
    <secondary_id>Eudract No. 2009-009940-22</secondary_id>
    <nct_id>NCT00887770</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart</brief_title>
  <official_title>A Single-centre, Double-blind, Double-dummy, Randomised, Placebo-controlled, Four-period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600 mg and 150 mg) on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (AveloxÂ®) as a Positive Control, in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being performed to investigate the potential for AZD5672 to affect the
      electrical conduction pathways in the heart. AZD5672 will be compared against a drug
      (moxifloxacin - a licensed antibiotic) known to have a detectable but safe change on the
      electrical conduction of the heart.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate time-matched QTcF intervals of single dose AZD5672 600mg compared to placebo.</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate time-matched QTcF Intervals of single dose AZD5672 150mg compared to placebo.</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the change in time matched ECG parameters (QTcB, QTcX, RR, PR and QRS) of single dose AZD5672 600mg and 150mg compared to placebo</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To further evaluate the safety and tolerability of single dose AZD5672 600mg and 150mg</measure>
    <time_frame>Adverse events assessed throughout the whole study. Safety monitoring (BP, safety blood samples and ECG) conducted frequently throughout study and up to 72 hours post dose on treatment visits.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600mg AZD5672 + Moxifloxacin placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg AZD5672 + Moxifloxacin placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AZD5672 placebo + Moxifloxacin 400mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AZD5672 placebo + Moxifloxacin placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5672</intervention_name>
    <description>12 x 50mg tablet, oral, single dose</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>1 x 400mg capsule, oral, single dose</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>12 x matched to AZD5672 50 mg tablet</description>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5672</intervention_name>
    <description>3 x 50mg tablet, oral. single dose</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>9 x matched to AZD5672 50mg tablet</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1 x matched to Moxifloxacin capsule</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) between 18 and 30 kg/m2 and a minimum weight of 50kg.

          -  Non-smoker

        Exclusion Criteria:

          -  Marked QTc prolongation at baseline e.g. repeated demonstration of QTc interval &gt;450ms
             or marked shortening of QTcF &lt;350ms

          -  Any clinically important abnormalities in rhythm, conduction or morphology of resting
             ECG that may interfere with the interpretation of the QTc Interval changes

          -  Use of concomitant medications that prolong QT/QTc interval
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Layton</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, Alderley Park, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Darren Wilbraham</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guys Drug Research Unit, Newcomen St, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2009</study_first_posted>
  <last_update_submitted>July 15, 2009</last_update_submitted>
  <last_update_submitted_qc>July 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>QTcF</keyword>
  <keyword>Crossover</keyword>
  <keyword>ICH E14</keyword>
  <keyword>QT/QTc prolongation</keyword>
  <keyword>Moxifloxacin</keyword>
  <keyword>QT/QTc Interval</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>N-(1-(3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-methanesulfonylphenyl)acetamide</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

